Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.
News: Clinical Trials
Vanderbilt investigators have conducted a prospective multicenter study on how extracorporeal photopheresis works in treating chronic graft-versus-host disease (cGVHD) — a complication of bone marrow or stem cell transplant that occurs when donor cells attack the recipient.
Jordan Berlin, MD, has been named associate director of Clinical Investigation Strategy and Shared Resources at Vanderbilt-Ingram Cancer Center (VICC). In his new role he will chair the Resource Allocation Committee and continue as chair of the Clinical Trials Shared Resource (CTSR) Steering Committee.
My Cancer Genome (MCG), a web-based cancer information tool developed by Vanderbilt-Ingram Cancer Center investigators in 2011 and supported by GenomOncology, has launched a new clinical trial search tool that allows website visitors to search for cancer clinical trials based on disease, biomarker, phase and recruiting status.
Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville. The first was to support her favorite hockey team, the Nashville Predators, and the second was to meet with Leora Horn, M.D., M.Sc., a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center (VICC). Shaw, 33, […]
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]
Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D., MPH, professor and chair of Urologic Surgery, and Sandeep Arora, […]
The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]